Overview
Location
United States, New Jersey, Rutherford
Employees
1001-5000
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 10, 2025 | EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy | Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidate EPY201 targeting focal refractory epilepsy (FRE) Future financings to adva... |
| Feb 28, 2024 | Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women’s Health and Femtech | MILAN–(BUSINESS WIRE)–February 28, 2024– Zcube – Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences. Starting ... |
| Oct 20, 2021 | Champions Oncology : Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus | DGAP-News: Champions Oncology, Inc. / Key word(s): Miscellaneous Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus 20.10.2021 / 14:00 The issuer is solely responsib... |
| Jun 16, 2017 | ZCube Launches Second Edition of Open Accelerator | ZCube, the research venture of Zambon, an Italian pharmaceutical and fine-chemical multinational company, has launched the second edition of Open Accelerator, a Milan, Italy-based fast track acceleration program for life science startup pro... |
| Jun 16, 2017 | ZCube announces the second edition of Open Accelerator: an international call for ideas for life sciences startups | Milan, 16th June, 2017 – ZCube, Research Venture of the pharmaceutical group Zambon, launches the second edition of Open Accelerator, a fast track acceleration program for life science start-up projects. Open Accelerator is a 12-steps progr... |
| May 22, 2016 | Zambon Launches Xadago® (Safinamide) in the U.K. for Patients with Mid- to Late-Stage Parkinson’s Disease | Zambon today announces the availability in the U.K. of Xadago® (safinamide) for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as an add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with... |
| Mar 16, 2016 | Zambon and US WorldMeds Partner to Bring Newron Pharmaceuticals’ Parkinson’s Disease Treatment Xadago® (safinamide) to the U.S. | Xadago® (safinamide) is already approved in the EU and Switzerland, under review by the U.S. Food and Drug Administration Drug candidate has potential to assist the more than one million Americans living with Parkinson’s MILAN–(BUSINESS WIR... |
| Feb 22, 2016 | Zambon Launches Xadago® (safinamide) in Spain for Patients with Mid- to Late-Stage Parkinson’s Disease | Spain is the third country in which Xadago® is available for the treatment of adult patients with idiopathic Parkinson’s disease (PD) MILAN–(BUSINESS WIRE)–February 22, 2016– Zambon S.p.A., an international pharmaceutical company strongly c... |
| Nov 13, 2015 | Swissmedic Approves Xadago® (Safinamide) for Use in Parkinson’s Disease | MILAN–(BUSINESS WIRE)–November 13, 2015– Zambon S.p.A., an International Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases, and its partner Newron Pharmaceuticals S.p.A. (“Newron”), a research and deve... |
Show more
Reviews 0
FAQ about Zambon
What has the press written about Zambon?
Parsers VC has collected 11 articles mentioning Zambon, among them “EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy” (Dec 10, 2025) and “Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women’s Health and F...” (Feb 28, 2024).
Is Zambon still active?
Yes, Zambon is active; its latest activity on Parsers VC dates from Dec 10, 2025.